Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Enveric Biosciences Inc (ENVB)

Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,480
  • Shares Outstanding, K 9,945
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,290 K
  • EBIT $ -9 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.80
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.56
  • Most Recent Earnings $-0.24 on 11/14/24
  • Next Earnings Date 11/18/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 1
  • High Estimate -0.40
  • Low Estimate -0.40
  • Prior Year -1.46
  • Growth Rate Est. (year over year) +72.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3323 +5.30%
on 11/18/24
0.5550 -36.95%
on 10/23/24
-0.0972 (-21.74%)
since 10/18/24
3-Month
0.3323 +5.30%
on 11/18/24
0.5790 -39.57%
on 08/21/24
-0.2299 (-39.65%)
since 08/20/24
52-Week
0.3323 +5.30%
on 11/18/24
2.9200 -88.02%
on 02/29/24
-1.1101 (-76.03%)
since 11/20/23

Most Recent Stories

More News
Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373

Enveric Biosciences, Inc. (NASDAQ: ENVB) is engaged as a biotechnology company, which focused on the research and development of innovative

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)
Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression,...

ENVB : 0.3499 (-1.44%)

Business Summary

Enveric Biosciences Inc. is a patient-centric biotechnology company endeavoring to enhance the lives of Cancer Treatments with novel cannabinoid medicines. Enveric Biosciences Inc., formerly known as AMERI Holdings Inc., is based in NAPLES, Fla.

See More

Key Turning Points

3rd Resistance Point 0.3916
2nd Resistance Point 0.3805
1st Resistance Point 0.3652
Last Price 0.3499
1st Support Level 0.3388
2nd Support Level 0.3277
3rd Support Level 0.3124

See More

52-Week High 2.9200
Fibonacci 61.8% 1.9315
Fibonacci 50% 1.6262
Fibonacci 38.2% 1.3208
Last Price 0.3499
52-Week Low 0.3323

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar